Neuro-oncology biotech industry progress report

被引：0
作者：
Shamik Chakraborty
Imithri Bodhinayake
Amrit Chiluwal
David J. Langer
Rosamaria Ruggieri
Marc Symons
John A. Boockvar
机构：
[1] Hofstra Northwell School of Medicine,Brain Tumor Biotech Center, Feinstein Institute for Medical Research
[2] Hofstra Northwell School of Medicine,Department of Neurological Surgery
[3] Lenox Hill Hospital,Department of Neurological Surgery and Otolaryngology/Head and Neck Surgery, Lenox Hill Brain Tumor Center
来源：
Journal of Neuro-Oncology | 2016年 / 128卷
关键词：
Glioblastoma; Brain tumors; Biotechnology;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The Brain Tumor Biotech Center at the Feinstein Institute for Medical Research, in collaboration with Voices Against Brain Cancer hosted The Brain Tumor Biotech Summit at in New York City in June 2015. The focus was once again on fostering collaboration between neuro-oncologist, neurosurgeons, scientists, leaders from biotechnology and pharmaceutical industries, and members of the financial community. The summit highlighted the recent advances in the treatment of brain tumor, and specifically focused on targeting of stem cells and EGFR, use of prophage and immunostimulatory vaccines, retroviral vectors for drug delivery, biologic prodrug, Cesium brachytherapy, and use of electric field to disrupt tumor cell proliferation. This article summarizes the current progress in brain tumor research as presented at 2015 The Brain Tumor Biotech Summit.
引用
收藏
页码：175 / 182
页数：7
相关论文
共 340 条
[1]  
Stupp R(2005)Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987-996
[2]  
Mason WP(2009)Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 27 4733-4740
[3]  
van den Bent MJ(2013)Industry progress report on neuro-oncology: Biotech update 2013 J Neurooncol 115 311-316
[4]  
Weller M(2013)Industry progress report on neuro-oncology: a biotech update J Neurooncol 112 315-321
[5]  
Fisher B(2002)Targeting death and decoy receptors of the tumour-necrosis factor superfamily Nat Rev Cancer 2 420-430
[6]  
Taphoorn MJ(2010)TRAIL receptor signaling and therapeutics Expert Opin Ther Targets 14 1091-1108
[7]  
Belanger K(2014)The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity Oncotarget 5 12728-12737
[8]  
Brandes AA(2015)Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway Mol Cancer 14 99-1432
[9]  
Marosi C(2015)Small-molecule ONC201/TIC10 targets chemotherapy-resistant colorectal cancer stem-like cells in an Akt/Foxo3a/TRAIL-dependent manner Cancer Res 75 1423-1674
[10]  
Bogdahn U(2015)Genetic and pharmacological screens converge in identifying FLIP, BCL2, and IAP proteins as key regulators of sensitivity to the TRAIL-inducing anticancer agent ONC201/TIC10 Cancer Res 75 1668-76
12345678910